Management of Gastrointestinal Bleeding in Systemic Lupus Erythematosus

Initial Assessment and Treatment

The European League Against Rheumatism recommends determining the underlying mechanism of gastrointestinal bleeding in patients with Systemic Lupus Erythematosus (SLE), differentiating between inflammatory mesenteric vasculitis and thrombosis/ischemia related to antiphospholipid antibodies, as this determines the treatment approach 1
Evaluating hematological manifestations, such as severe thrombocytopenia (platelets <30,000/mm³), is crucial as it can coexist and contribute to bleeding, requiring simultaneous management 1
Patients with positive antiphospholipid antibodies require anticoagulation in addition to immunosuppression 1, 2

High-dose methylprednisolone pulses (500-1000 mg/day for 1-3 days) are recommended as initial treatment, with an expected response within 24-48 hours 1
Moderate to high doses of oral prednisone (equivalent to 0.5-1 mg/kg/day) should follow the pulses 1
Adding an immunosuppressive agent, such as cyclophosphamide, is recommended for severe disease with vital risk, or considering mycophenolate mofetil or azathioprine to facilitate corticosteroid reduction 1, 3

If platelets are <30,000/mm³, initiating methylprednisolone pulses (1-3 days) plus an immunosuppressive agent (azathioprine, mycophenolate mofetil, or cyclosporine) is recommended 1
Intravenous immunoglobulin (IVIG) may be considered in the acute phase, especially if there is an inadequate response to corticosteroids or to avoid infectious complications 1

Anticoagulation with warfarin (target INR 2.0-3.0 for first venous thrombosis; 3.0-4.0 for arterial or recurrent thrombosis) is recommended for patients with positive antiphospholipid antibodies 3
Combined therapy with immunosuppression and anticoagulation/anti-thrombotics may be necessary when both inflammatory and thrombotic mechanisms coexist 1

The goal is to reduce corticosteroids to <7.5 mg/day of prednisone equivalent for chronic maintenance, using immunosuppressive agents to facilitate this reduction 1, 3
Calcium and vitamin D supplementation is recommended for patients on long-term corticosteroids 3